AI-generated analysis. Always verify with the original filing.
Assembly Biosciences, Inc. reported financial results for the year ended December 31, 2025, with collaboration revenue of $72.3 million, net loss of $6.1 million or $0.55 per share, and cash, cash equivalents, and marketable securities of $248.1 million projected to fund operations into 2028. Highlights include licensing its helicase-primase inhibitor program to Gilead for a net $35 million option fee.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth
Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press Release issued March 19, 2026 104 Cover Page Interactive Data File (embe